Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs by Hebel, Tobias et al.
Vol.:(0123456789) 
European Archives of Psychiatry and Clinical Neuroscience 
https://doi.org/10.1007/s00406-021-01287-3
ORIGINAL PAPER
Antidepressant effect of repetitive transcranial magnetic stimulation 
is not impaired by intake of lithium or antiepileptic drugs
T. Hebel1  · M. A. Abdelnaim1 · M. Deppe1 · P. M. Kreuzer1 · A. Mohonko1,2 · T. B. Poeppl1,3 · R. Rupprecht1 · 
B. Langguth1 · M. Schecklmann1
Received: 4 January 2021 / Accepted: 21 June 2021 
© The Author(s) 2021
Abstract
Introduction The effect of concomitant medication on repetitive transcranial magnetic stimulation (rTMS) outcomes in 
depression remains understudied. Recent analyses show attenuation of rTMS effects by antipsychotic medication and ben-
zodiazepines, but data on the effects of antiepileptic drugs and lithium used as mood stabilizers or augmenting agents are 
sparse despite clinical relevance. Preclinical electrophysiological studies suggest relevant impact of the medication on treat-
ment, but this might not translate into clinical practice. We aimed to investigate the role of lithium (Li), lamotrigine (LTG) 
and valproic acid (VPA) by analyzing rTMS treatment outcomes in depressed patients.
Methods 299 patients with uni- and bipolar depression treated with rTMS were selected for analysis in respect to intake of 
lithium, lamotrigine and valproic acid. The majority (n = 251) were treated with high-frequency (10–20 Hz) rTMS of the 
lDLPFC for an average of 17 treatment sessions with a figure-of-8 coil with a MagVenture system aiming for 110% resting 
motor threshold, and smaller groups of patients were being treated with other protocols including intermittent theta-burst 
stimulation and bilateral prefrontal and medial prefrontal protocols. For group comparisons, we used analysis of variance 
with the between-subjects factor group or Chi-Square Test of Independence depending on the scales of measurement. For 
post-hoc tests, we used least significant difference (LSD). For differences in treatment effects between groups, we used an 
ANOVA with the between-subjects factor group (groups: no mood stabilizer, Li, LTG, VPA, Li + LTG) the within-subjects 
factor treatment (pre vs. post treatment with rTMS) and also Chi-Square Tests of independence for response and remission.
Results Overall, patients showed an amelioration of symptoms with no significant differences for the main effect of group 
and for the interaction effect treatment by group. Based on direct comparisons between the single groups taking mood sta-
bilizers against the group taking no mood stabilizers, we see a superior effect of lamotrigine, valproic acid and combination 
of lithium and lamotrigine for the response and remission rates. Motor threshold was significantly and markedly higher for 
patients taking valproic acid.
Conclusion Being treated with lithium, lamotrigine and valproic acid had no relevant influence on rTMS treatment outcome. 
The results suggest there is no reason for clinicians to withhold or withdraw these types of medication from patients who are 
about to undergo a course of rTMS. Prospective controlled work on the subject is encouraged.
Keywords Depression · Repetitive transcranial magnetic stimulation · rTMS · Lithium · Lamotrigine · Valproic acid · 
Mood stabilizer
Introduction
The necessity of adding innovative treatment strategies for 
the treatment of Major Depressive Disorder arises from the 
unsatisfactory state of purely pharmacological and psycho-
therapeutic treatment, which leaves a significant number of 
patients failing to reach remission [35].
Non-invasive brain stimulation by repetitive transcranial 
magnetic stimulation (rTMS) is an increasingly common, 
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safe, and evidence-based adjunct therapy [20, 24, 28]. The 
most encouraging evidence for the use of rTMS in depres-
sion has come from large sham-controlled trials in which 
patients were required to be medication-free while receiv-
ing treatment [8, 26]. While methodologically sound from a 
scientific perspective, translating the results from such tri-
als into everyday clinical practice can be challenging, as 
patients are rarely referred to rTMS services as a first-line 
treatment and are more often than not taking a number of 
psychiatric drugs [25].
There is growing evidence that concomitant use of medi-
cation can have influence on the clinical effectiveness of 
rTMS. For example, intake of benzodiazepines or antipsy-
chotics lowers the efficacy [12, 15], although for the case of 
antipsychotics there is also evidence to the contrary [30]. 
For the case of the benzodiazepine lorazepam, retrospec-
tive analysis has found its [5] use to be associated with 
decreased effectiveness and response rates to rTMS. This 
finding is compatible with preclinical considerations, as the 
anti-depressive action of rTMS may depend crucially on 
the propagation of the stimulation effects from the primary 
rTMS target site to connected downstream neurocircuitries 
[5]. This propagation process in turn can be attenuated by 
benzodiazepines, such as midazolam [6], alprazolam or diaz-
epam [27] in human subjects. However, pooled analysis by 
Fitzgerald et al. from two clinical trials could identify no 
difference in clinical depression outcomes between patients 
taking versus not taking benzodiazepines [7].
Other drugs commonly used in depressed patients have 
been studied less so far.
Lithium is one of the most studied and effective drugs in 
treating bipolar disorder, preventing both relapses of mania 
and depression and is counted among the “mood stabiliz-
ers” [23, 34]. Its use is not limited to bipolar disorder, and 
it is widely prescribed as an augmentation agent in unipolar 
depression with pronounced anti-suicidal effects [34].
Evidence from healthy volunteers suggests that lithium 
modulates corticospinal excitability and brain stimulation 
induced cortical plasticity [14, 36]. However, the conse-
quences for brain stimulation practice remain elusive, espe-
cially considering that the effects of lithium “are most pro-
nounced in the presence of pathology” [23], limiting the 
applicability of data from healthy volunteers.
Antiepileptic drugs are prescribed not only for epilepsy, 
but also for psychiatric disorders. Amongst the antiepileptic 
drugs, valproic acid (VPA), carbamazepine and lamotrigine 
(LTG) have been found to be of particular usefulness in the 
treatment of bipolar disorder [1]. However, clinicians have 
also begun testing the usefulness of these drugs in augmen-
tation of unipolar depression [9–11, 32].
Regarding electrophysiological parameters, there is evi-
dence from preclinical studies in healthy volunteers that 
LTG can elevate motor threshold, perhaps without changing 
intracortical excitability [19, 22, 37] and can modulate so 
called TMS-induced long-term potentiation-like plasticity 
[4, 13].
For VPA, studies in healthy volunteers found no effect on 
motor threshold [22, 38] or other TMS-derived electrophysi-
ological parameters [38]. More studies have been performed 
on epileptic patients, but their applicability to the subject 
seems even more limited as the drug effects in epileptic 
patients probably “represent a correction of intrinsic defects 
of the epileptic brain” [33].
It must be stressed once again that the majority of these 
findings come from application of brief, research-protocol 
TMS interventions and single-dose drug challenges in 
healthy subjects and the derived electrophysiological param-
eters mostly refer to the motor system.
Therefore, there remains a substantial gap to bridge 
between these preclinical findings and the treatment of 
depressed patients receiving daily rTMS and daily medica-
tion over the course of weeks [15, 25]. We aimed to inves-
tigate the role of Li, LTG and VPA by analyzing rTMS 
treatment outcomes in depressed patients taking versus 
not taking these drugs in a retrospective naturalistic study. 
While such a study design cannot elucidate the molecular 
mechanisms of rTMS or the drugs in question, it can offer 
some insight into the important clinical question whether 
these drugs interfere with rTMS treatment in a clinically 
meaningful way.
Methods
A cohort of patients with depression were treated with rTMS 
in the Center for Neuromodulation Regensburg (Germany) 
between 2002 and 2017. Patients gave written informed con-
sent to treatment. The retrospective analysis of clinical data 
was approved by the local ethics committee of the University 
of Regensburg (16-104-0223) and is in accordance with the 
ethical standards laid down in the Declaration of Helsinki. 
We have reported on this sample before with regards to other 
psychotropic medication classes and their effects on rTMS 
outcomes [5, 12].
The inclusion criteria were: naïve to rTMS (only the 
patient’s first treatment with rTMS was considered), diag-
nosis of depression according to ICD-10 of F31-F33, a 
completed Hamilton Depression Rating Scale with 21 items 
(HDRS-21) at beginning and at the end of the rTMS treat-
ment and absence of a serious somatic illness. Both in- and 
outpatients were included. Based on these criteria, a sample 
of 299 patients could be pre-selected for this analysis. Most 
of the patients did not take any mood stabilizer (n = 188), 
followed by a large group of patients taking lithium (n = 65) 
and smaller groups (n < 20) taking other mood stabilizers 
(one or two). No single patient took carbamazepine. Two 
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patients taking lithium and valproate and two patients taking 
lamotrigine and valproate were excluded from analysis due 
to small and thus not representative sample size (Table 1).
Exact numbers and also descriptive sample characteristics 
of the remaining 295 patients can be seen in Table 1 (see 
results). Different study protocols were used—the major-
ity of patients (n = 251) were treated with high-frequency 
protocols over the left DLPFC (227 with 20 Hz and 2000 
pulses, 15 with 10 Hz and 2000 pulses, 8 with 10 Hz and 
1000 pulses, 1 with 1 Hz and 2000 pulses). Four patients 
were stimulated over the right DLPFC (three with 20 Hz 
and 2000 pulses, 1 with 1 Hz and 1000 pulses), 12 over the 
medial prefrontal cortex with 10 Hz and 2000 pulses and 
28 were stimulated over both the left and right DLPFC in 
consecutive order (12 with 1 Hz right followed by 10 Hz left, 
each site with 1000 pulses; 16 with cTBS right followed by 
iTBS left, each site with 1200 pulses). Average number of 
treatment days was 17 and treatment was performed 5 days 
a week with no treatment on weekends. High-frequency pro-
tocols were applied with 50 pulses in a train and an inter-
train interval of 25 s. For low-frequency protocols, no pauses 
were included. Each treatment was performed with a Mag-
Venture system (MagVenture Inc., USA) using a figure-of-8 
coil (except a double cone coil for medial prefrontal cortex 
stimulation) aiming for a target treatment intensity of 110% 
resting motor threshold (except TBS protocols (80% resting 
motor threshold) and medial prefrontal cortex (100% resting 
motor threshold)). The upper limit of treatment intensity was 
set to 60% of stimulator output for safety and tolerability 
reasons.
All data were analyzed using SPSS (IBM Corp., 
USA; Version 24.0.0.0). The significance level was set at 
p < 0.05. For group comparisons, we used analysis of vari-
ance (ANOVA) with the between-subjects factor group 
(groups: no mood stabilizer, Li, LTG, VPA, Li + LTG) or 
Chi-Square-Test of Independence depending on the scales 
Table 1  Characteristics of patients with depression taking vs. not taking mood stabilizers (data in brackets represent 95% confidence intervals; 
categorial variables are presented in absolute and relative frequencies)
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of measurement. For post hoc tests, we used least signifi-
cant difference (LSD). For differences in treatment effects 
between groups, we used an ANOVA with the between-
subjects factor group (see above) and the within-subjects 
factor treatment (pre vs. post treatment with rTMS) and also 
Chi-Square-Tests of independence for response (decrease 
of HDRS score of at least 50% from pre to post rTMS) and 
remission (HDRS score at end of treatment below 11 points) 
rates. Results of chi-square tests were replicated by repeat-
ing them with the Fisher’s exact test for reasons of low cell 
frequencies.
Based on these data, number needed to treat (NNT) and 
number needed to harm (NNH) were calculated (Lenhard 
W, 2016, J, 1988). To control for effects of taking mood 
stabilizers at all and to control for effects of age, gender, 
intake of benzodiazepines, intake of antipsychotics, and 
type of depression, we repeated the ANOVA once with 
the factor group (no mood stabilizer vs. mood stabilizer) 
and once with the covariates age, gender, intake of ben-
zodiazepines (yes, no), intake of antipsychotics (yes, no), 
and type of depression.
Antidepressive treatment outcome was assessed by 
the Hamilton Depression Rating Scale with 21 items 
(HDRS-21).
Results
Groups did not differ with respect to age, sex, number of 
treatment sessions, number of pulses per session and base-
line depressive symptoms (HDRS), but differed with respect 
to resting motor threshold, stimulation intensity (near sig-
nificant), type and severity (near significant) of depression.
Groups differed also (near) significantly with respect 
to the intake of benzodiazepines and antipsychotics (see 
Table 1) showing increased intake of antipsychotics in the 
group of patients taking Li, LTG and Li + LTG and also 
increased intake of benzodiazepines in the group of patients 
taking Li and LTG.
Post hoc LSD tests indicated significant increased rest-
ing motor threshold and stimulation intensity for the group 
of patients taking VPA in contrast to the other groups (all 
p-values < 0.05 (see Fig. 3). As seen in the scatter plot, there 
Fig. 1  a Changes in HDRS-21 
sum score from pre- to post-
repetitive transcranial magnetic 
stimulation for patients taking 
different medication. Error bars 
represent 95% confidence inter-
vals. a2 Corresponding scatter 
plot. b Changes in HDRS scores 
expressed as percentual changes 
from pre to post treatment for 
patients taking different medica-
tion. Error bars represent 95% 
confidence intervals. b2 Cor-
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was one outlier (see Fig. 3a). Excluding this outlier from 
the ANOVA would result in a non-significant main effect of 
group (F = 1.413; df = 4289; p = 0.230).
All other post hoc groups’ contrasts were not signifi-
cant. Descriptive analyses of group differences for type of 
depression showed increased number of bipolar patients in 
the groups taking mood stabilizer and decreased number 
of patients with bipolar depression in the group taking no 
mood stabilizer. For severity of depression, there was no 
clear systematic unequal distribution for the single groups.
Overall, patients showed an amelioration of symptoms as 
indicated by a significant effect of treatment (F = 118.539; 
df = 1290; p < 0.001) with no significant differences for the 
main effect of group (F = 1.583; df = 4290; p = 0.179) and 
for the interaction effect treatment by group (F = 0.861; 
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Fig. 1  (continued)
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We also calculated chi-square tests of independence for the 
variables response/remission and medication group and did not 
see significant effects (see Fig. 2). Based on direct compari-
sons between the single groups taking mood stabilizer against 
the group taking no mood stabilizer, we see a superior effect 
LTG, VPA and Li + LTG for the response and remission rates 
only on a descriptive level. This is evident by NNT of 10 for 
LTG, 14 of VPA and 11 for Li + LTG for response and of 846 
for LTG, 12 of VPA and 5 for Li + LTG for remission. Effects 
were inferior for lithium for response (− 32) and remission 
(− 33) which is shown by numbers needed to harm (negative 
NNT).
Grouping the four subgroups taking mood stabilizers 
together revealed the same findings for the ANOVA (main 
effect treatment: p < 0.001; main effect group: p = 0.861; inter-
action effect: p = 0.457). Including relevant covariates also 
resulted in the same findings (main effect treatment: p < 0.001; 
main effect group: p = 0.158; interaction effect: p = 0.501).
Relative changes showed no differences between groups.  
 (Cohen’s d, [16]), achieved power and needed sample size 
(equal-sized samples, with an alpha threshold of 5%, two-sided 
test, power of 80%) using the contrasts groups taking mood 
stabilizer against the single groups taking no mood stabilizer 
showed negligible effect sizes and low power for all contrasts 
(Li: d = 0.075, power = 8%, needed sample size of 5566; LTG: 
d = 0.229, power = 15%, needed sample size of 600; VPA: 
d = 0.262, power = 19%, needed sample size of 460) except for 
the contrast Li + LTG showing medium effect size and power 
(d = 0.581, power = 52%, needed sample size of 96).
Discussion
Our retrospective analysis suggests that being treated with 
lithium, LTG or VPA may have no statistically significant or 
clinically relevant influence on rTMS treatment outcomes in 
depression. Values for NNT or NNH were low (NNT of 10 
for the response rate for LTG means that ten patients would 
have to be treated with LTG additionally to rTMS to get one 
more patient with response in contrast to the group with 
Fig. 3  Resting motor threshold 
and stimulation intensity for 
patients taking different medica-
tion. Error bars represent 95% 
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Fig. 2  Response and remission rates for patients taking different med-
ication
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only rTMS). In addition, cell frequencies for LTG, VPA and 
Li + LTG were low and minimal changes would lead to large 
changes in NNT or NNH. Thus, effects of this co-medication 
is at least small or negligible and can only be confirmed in 
even larger samples sizes.
If validated, this means there is no reason for clinicians 
to withhold or withdraw these types of medication from 
patients who are about to undergo a course of rTMS. From 
own clinical experience, referring physicians and patients 
are often concerned about these medications attenuating 
rTMS effects. Our presented data may provide a prelimi-
nary evidence base for making that decision in favor of 
continuing the mood stabilizing agents. This is in line with 
recent work by Hunter et al. who reported benzodiazepines 
and psychostimulants to influence rTMS outcomes, but 
found no effect for antiepileptic drugs [15].
Controlling for confounding factors suggests that age, 
gender, intake of benzodiazepines or antipsychotics and 
type of depression do not account for the lack of outcome 
differences.
Motor threshold was significantly and markedly higher 
for patients taking VPA, fitting the findings in epileptic 
patients on long-term VPA regimens [2, 18]. This rein-
forces the hypothesis that long-term administration of 
the drug has different effects on cortical excitability than 
single-dosing protocols. This effect was not seen for the 
other mood stabilizing drugs in our sample. The result is 
somewhat limited however, since the effect is not sustain-
able if the outlier (see Fig. 3a) is excluded from analysis, 
highlighting further the need for larger sample sizes.
Higher MTs did translate into higher stimulation intensi-
ties (near significant main effect of group and significant 
group contrasts) in our patient population on VPA. How-
ever, differences between groups were numerically higher 
for MTs than for stimulation intensities which is due to a 
ceiling effect, as it is common practice in our rTMS setting 
to limit treatment intensity to 60% of stimulator output for 
safety and tolerability reasons. Still, the VPA group did not 
have worse clinical outcomes despite this intensity limita-
tion. While patient numbers were low for VPA intake, this 
finding fits with the point made by Minzenberg and Leuchter 
that antiepileptic drugs such as VPA “may decrease cortical 
excitability without affecting cortical plasticity” [25].
Strengths of our study include the comparatively large 
number of patients analyzed and the novelty and poten-
tially large clinical relevancy of the results. The results 
from our study are compatible with the analysis by Fitzger-
ald et al. [7], which showed no difference in clinical rTMS 
outcomes for patients taking versus not taking benzodiaz-
epines, another medication class for which preclinical evi-
dence pointed towards possibly attenuating rTMS effects.
The main limitation of our paper is obviously the 
methodological issue of retrospective analysis. We still 
predict prospective controlled work on the matter to be 
challenging due to ethical and practical considerations. 
Giving lithium or antiepileptic drugs to depressed patients 
or withholding them over weeks despite clinical necessity 
for the purpose of studying rTMS effects provides major 
ethical and practical challenges.
In case of all drugs except lithium, limited sample size 
is another issue. Small sample size for the groups taking 
LTG, VPA and Li + LTG and the unbalanced distribu-
tion of the groups stem from the naturalistic prescription 
practice of these drugs, but of course limit the validity of 
the results. Achieving adequate statistical power would 
require even larger clinical samples that ours as stated in 
the results section. Unequal sample sizes might lead to the 
missing effect stemming from type II error.
Our practice to limit treatment intensity at 60% stimula-
tor output and the use of comparatively low intensities for 
medial prefrontal cortex stimulation and the iTBS treat-
ments in this sample might potentially lead to less-than-
optimal treatment outcomes when compared to the higher 
intensities in prospective controlled studies. This in turn 
may lead to the additional limitation of less sensitivity 
to detect potential differences between the groups, again 
owing to the nature of retrospective clinical analysis.
We also do not have systematic data on the grade 
of treatment resistance of the patients. We do however 
assume a medium to high level of treatment resistance, 
as these were inpatients at a tertiary hospital and rTMS is 
currently practically always used only if several courses 
of medication have not led to remission.
Since the analysis was performed retrospectively, we 
had no data on blood levels of the drugs. However, it 
is common practice in the treatment center to regularly 
monitor levels of VPA and lithium, so the possibility of 
noncompliance was at least somewhat mitigated. On the 
other hand, it is not clear if the effects of long-term VPA 
on electrophysiological measures are at all dependent on 
the current blood level or may reflect chronic changes in 
cortical physiology.
However, despite these limitations the authors are con-
vinced that—given the scarcity of available data on the sub-
ject—the analyses presented in this manuscript may provide 
a rationale for further administration of mood stabilizing 
drugs when administering rTMS and may serve as a ground-
work for further clinical studies.
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